Rogelio Cantu
Optometrist · Harlingen, TXNPI 1720020316
Payments from drug & device makers
Across 586 payments — averaging $31.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$2K
- Oyster Point Pharma, Inc.$2K
- AbbVie$2K
- Alcon$2K
- Novartis$2K
- Aerie Pharmaceuticals, Inc.$1K
- plus $8K from 25 others
What the payments were for
- Speaking & faculty fees$5003%
- Food & beverage$18,02097%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 90 | $2,081 |
| Oyster Point Pharma, Inc. | 55 | $1,879 |
| AbbVie(2 entities) | 66 | $1,865 |
| Alcon | 51 | $1,607 |
| Novartis | 93 | $1,562 |
| Aerie Pharmaceuticals, Inc. | 21 | $1,142 |
| Eyevance Pharmaceuticals LLC | 31 | $1,074 |
| Coopervision Inc. | 29 | $829 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 37 | $694 |
| Biotissue Holdings Inc. | 9 | $671 |
| Sun Pharmaceutical Industries Inc. | 16 | $630 |
| Glaukos Corporation | 5 | $516 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $495 |
| Shire North American Group Inc | 10 | $450 |
| Genentech USA, Inc. | 6 | $439 |
| Dompe US, Inc. | 13 | $418 |
| Sight Sciences, Inc. | 4 | $360 |
| Regeneron Healthcare Solutions, Inc. | 5 | $300 |
| Kala Pharmaceuticals, Inc. | 13 | $272 |
| Tarsus Pharmaceuticals, Inc. | 7 | $234 |
| Apellis Pharmaceuticals, Inc. | 4 | $188 |
| Mallinckrodt Hospital Products Inc. | 2 | $152 |
| Harrow Eye, LLC | 1 | $148 |
| Rxsight Inc | 1 | $145 |
| ANI Pharmaceuticals, Inc. | 1 | $115 |
| Amgen | 1 | $86 |
| Lombart Brothers, Inc. | 1 | $60 |
| Thea Pharma Inc. | 2 | $42 |
| Astellas Pharma US Inc | 2 | $36 |
| Tearlab Corp | 1 | $16 |
| Eyepoint US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$1,265
- Rocklatan$667
- Flarex$663
- TYRVAYA$623
- MIEBO$560
- Rhopressa$557
- VABYSMO$371
- CEQUA$336
- VYZULTA$331
- Oxervate$246
- LUMIGAN$241
- DURYSTA$234
- Prokera$221
- MyDay Contact Lens$214
- TRYPTYR$150
- VEVYE$148
- RXSIGHT CONTACT LENS$145
- RXSIGHT INJECTOR CARTRIDGE$145
- RXSIGHT INJECTOR HANDPIECE$145
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$145
How this compares
$18,520 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 230 | $243,145 |
| XiidraLifitegrast | 198 | $206,768 |
| LumiganBimatoprost | 322 | $154,508 |
| EysuvisLoteprednol Etabonate | 222 | $154,280 |
| Cyclosporine | 135 | $77,960 |
| XdemvyLotilaner | 39 | $72,514 |
| MieboPerfluorohexyloctane/Pf | 60 | $46,004 |
| TyrvayaVarenicline Tartrate | 44 | $41,506 |
| FlarexFluorometholone Acetate | 206 | $41,487 |
| CombiganBrimonidine Tartrate/Timolol | 124 | $35,588 |
| ProlensaBromfenac Sodium | 59 | $28,346 |
| RhopressaNetarsudil Mesylate | 39 | $21,803 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 116 | $19,868 |
| RocklatanNetarsudil Mesylat/Latanoprost | 30 | $17,637 |
| Ketorolac Tromethamine | 295 | $15,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Restasis Multidose | $1,865 | $442,279690 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta, Zirgan | $2,081 | $266,954292 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $272 | $154,280222 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $234 | $72,51439 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax, Lotemax Sm | $694 | $54,436146 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $1,879 | $41,50644 claims |
| Eyevance Pharmaceuticals LLCFlarex | $1,074 | $41,487206 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $1,142 | $39,44069 claims |
| AlconSimbrinza | $1,607 | $4,85924 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Harlingen
- Lauro GuerreroHarlingen$133K
- Tiffany HuynhHouston$3.2M
- Bridgitte LeeHouston$3M
- Bryan FrazierTyler$1.4M
- Derek CunninghamAustin$940K
- Wendy ChungKaty$900K
- Phillip BrunsonHouston$766K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$568K
- Mina VanrachackSan Antonio$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.